mechlorethamine has been researched along with Lymphoma, Follicular in 11 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
Lymphoma, Follicular: Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
Excerpt | Relevance | Reference |
---|---|---|
"We reviewed all reported cases of Burkitt's lymphoma and/or Burkitt's leukemia (BLL) occurring following therapy for Hodgkin's disease." | 2.39 | Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. ( Cooper, DL; Levy, A; Salloum, E; Tallini, G, 1996) |
"The natural history of follicular lymphoma is believed not to have changed over the last 30 years." | 1.33 | New treatment options have changed the survival of patients with follicular lymphoma. ( Fisher, RI; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Unger, JM, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (54.55) | 18.7374 |
1990's | 3 (27.27) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Régis, A | 1 |
Ben Salem, D | 1 |
Lambert, A | 1 |
Couaillier, JF | 1 |
Casasnovas, O | 1 |
Piard, F | 1 |
Krausé, D | 1 |
MOLANDER, DW | 1 |
HALNAN, KE | 1 |
RABENKO, J | 1 |
CORREA URQUIZA, LM | 1 |
Fisher, RI | 2 |
LeBlanc, M | 1 |
Press, OW | 1 |
Maloney, DG | 1 |
Unger, JM | 1 |
Miller, TP | 1 |
Longo, DL | 1 |
Young, RC | 1 |
Hubbard, SM | 1 |
Wesley, M | 1 |
Jaffe, E | 1 |
Berard, C | 1 |
DeVita, VT | 1 |
Portlock, CS | 1 |
Jurcic, JG | 1 |
Koll, B | 1 |
Brown, AE | 1 |
Crown, JP | 1 |
Yahalom, J | 1 |
Gulati, SC | 1 |
Salloum, E | 1 |
Tallini, G | 1 |
Levy, A | 1 |
Cooper, DL | 1 |
Solal-Céligny, P | 1 |
Rywlin, AM | 1 |
Recher, L | 1 |
Hoffman, EP | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma[NCT02008006] | Phase 2 | 21 participants (Actual) | Interventional | 2014-07-09 | Terminated (stopped due to Insufficient recruitment and unavailability of the treatment) | ||
Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647] | Phase 2 | 4 participants (Actual) | Interventional | 2020-11-23 | Completed | ||
A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas[NCT00003784] | Phase 2 | 102 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction
Intervention | Participants (Count of Participants) |
---|---|
Ublituximab Only | 2 |
"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction
Intervention | Participants (Count of Participants) |
---|---|
Ublituximab Only | 2 |
Ublituximab First, Then Ublituximab and Umbralisib | 2 |
"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction
Intervention | Participants (Count of Participants) |
---|---|
Ublituximab Only | 2 |
Ublituximab First, Then Ublituximab and Umbralisib | 2 |
2 reviews available for mechlorethamine and Lymphoma, Follicular
Article | Year |
---|---|
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide | 1996 |
[Follicular lymphomas. Therapeutic indications].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1992 |
9 other studies available for mechlorethamine and Lymphoma, Follicular
Article | Year |
---|---|
[Concomitant pulmonary Langerhans cell histiocytosis and malignant lymphoma: report of two cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Combined Modality Therapy; | 2009 |
THE MALIGNANT LYMPHOMAS.
Topics: Adrenal Cortex Hormones; Chlorambucil; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma | 1963 |
LONG-TERM RESULTS OF X-RAY TREATMENT IN MALIGNANT DISEASE OF THE LYMPHO-RETICULAR SYSTEM.
Topics: Classification; England; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodg | 1964 |
[The use of nitrogen mustard in the treatment of lymphatic diseases of a malignant type].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, | 1959 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
Prolonged initial remission in patients with nodular mixed lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1984 |
Deferral of initial therapy for advanced indolent lymphomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therap | 1982 |
Excretion of Ascaris lumbricoides during total body irradiation.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascariasis; Ascaris lumbricoides; Bo | 1994 |
Lymphoma-like presentation of Kaposi's sarcoma. Three cases without characteristic skin lesions.
Topics: Aged; Blood; Blood Protein Electrophoresis; Diagnosis, Differential; Female; Hodgkin Disease; Humans | 1966 |